Merck Enter Into Licensing Agreement With Sun Pharma For Tildrakizumab

Sun Pharma (NSE: SUNPHARMA) will have exclusive worldwide rights from Merck (NYSE: MRK) to commercialize MK-3222 (Tildrakizumab), an agent currently being studied in a Phase 3 clinical trial for the treatment of chronic plaque psoriasis, an inflammatory skin condition.

sun_mrk_logo.png

Source: Wiki

Humanized-monoclonal antibody, Tildrakizumab, works by blocking a "signaling molecule" known as cytokine IL-23, believed to mediate inflammatory processes.

According to the licensing terms, Sun is required to pay Merck an upfront fee of $80 million; moreover, the Mumbai, India-based Company will be responsible for all development fees, covering subsequent regulatory filings, as well as, postmarketing surveillance.

Even More. Merck & Co., a global pharmaceutical giant – having presence in more than 140 countries – will continue to run the ongoing late-stage trial. Moreover, the New Jersey firm is eligible to receive various undisclosed sales milestones, in addition to tiered royalties roughly 5% to 10% of net sales.

The specialty biopharma Sun, based in Mumbai India, manufactures and markets both generics and branded drugs and operating in global markets not limited to the United States and India.

Bottom Line. This licensing deal with Merck added Tildrakizumab to Sun's branded portfolio, which focuses on clinical areas, such as cardiology, psychiatry, neurology, gastroenterology, diabetetology and respiratory. Sun also has 170 active pharmaceutical ingredients or "APIs."

Read More at Retail Investor 360

Disclosure: We are long on SPPI.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.